Announcements Trials
Browse Landscape

Phase

Phase NA 10Phase 2 9Phase 3 4Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 3Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 10Glioma 9Glioblastoma 8Sarcoma 7Pancreatic Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Brain Neoplasms 5Recurrence 4Neuroendocrine Tumors 4Neuroblastoma 4Lymphoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Melanoma 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Smoldering Multiple Myeloma 2Smoking Cessation 2Smoking 2Skin Neoplasms 2Sarcoma, Alveolar Soft Part 2

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × Carcinoma, Intraductal, Noninfiltrating × Clear all
NCT02872025 2025-01-30

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

University of California, San Francisco

Phase EARLY_PHASE1 Active not recruiting
42 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡